# CCNE1

Source: https://onco.cc/targets/ccne1/  
OnCo record `ccne1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CCNE1 (G1/S-specific cyclin-E1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.

## Summary

Essential for the control of the cell cycle at the G1/S (start) transition.

CIViC holds 16 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib, Dinaciclib, CDK Inhibitor SNS-032 and Camonsertib and others. Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes affected pathway 0.57, literature 0.99, genetic association 0.57, somatic mutation 0.96, animal model 0.64). In OnCo, 1 product record names it (AVZO-021).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: cyclin E1; G1/S-specific cyclin-E1
- Tags: cancer-genes-wave
- Symbol: CCNE1
- Class: other
- Biology: Essential for the control of the cell cycle at the G1/S (start) transition. Location: Nucleus (UniProt). Locus 19q12 (HGNC).
- Where found: Gastric & gastro-oesophageal junction cancer: Open Targets association 0.51 with gastric cancer (MONDO_0001056); CIViC evidence names this disease; Breast cancer: Open Targets association 0.50 with breast cancer (MONDO_0007254); CIViC evidence names this disease; Ovarian cancer: CIViC evidence names this disease; Endometrial cancer: CIViC evidence names this disease; Colorectal cancer: Open Targets association 0.58 with colorectal cancer (MONDO_0005575); Bladder & urothelial cancer: Open Targets association 0.52 with urinary bladder cancer (MONDO_0001187)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 10 therapies; CIViC holds 16 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Gastric Adenosquamous Carcinoma; Ovarian Serous Cystadenocarcinoma; Endometrial Serous Adenocarcinoma.

## Sources

- HGNC HGNC:1589: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1589
- UniProt P24864: https://www.uniprot.org/uniprotkb/P24864/entry
- NCBI Gene 898: https://www.ncbi.nlm.nih.gov/gene/898
- Ensembl ENSG00000105173: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105173

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- drugs: [AVZO-021](https://onco.cc/drugs/avzo-021/)
- pathways: [Synthetic lethality: paired dependencies](https://onco.cc/pathways/synthetic-lethality-map/)

---
JSON: https://onco.cc/api/v1/entities/ccne1.json